- Home
- ARQQ vs TYRA Comparison
ARQQ vs TYRA Comparison
Compare ARQQ & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQQ
- TYRA
- Stock Information
- Founded
- ARQQ 2017
- TYRA 2018
- Country
- ARQQ United Kingdom
- TYRA United States
- Employees
- ARQQ N/A
- TYRA N/A
- Industry
- ARQQ Computer Software: Prepackaged Software
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- ARQQ Technology
- TYRA Health Care
- Exchange
- ARQQ Nasdaq
- TYRA Nasdaq
- Market Cap
- ARQQ 531.6M
- TYRA 571.9M
- IPO Year
- ARQQ N/A
- TYRA 2021
- Fundamental
- Price
- ARQQ $30.41
- TYRA $12.88
- Analyst Decision
- ARQQ Strong Buy
- TYRA Strong Buy
- Analyst Count
- ARQQ 1
- TYRA 7
- Target Price
- ARQQ $52.00
- TYRA $30.43
- AVG Volume (30 Days)
- ARQQ 366.1K
- TYRA 208.6K
- Earning Date
- ARQQ 05-22-2025
- TYRA 08-14-2025
- Dividend Yield
- ARQQ N/A
- TYRA N/A
- EPS Growth
- ARQQ N/A
- TYRA N/A
- EPS
- ARQQ 0.48
- TYRA N/A
- Revenue
- ARQQ $241,000.00
- TYRA N/A
- Revenue This Year
- ARQQ $284.30
- TYRA N/A
- Revenue Next Year
- ARQQ $415.45
- TYRA N/A
- P/E Ratio
- ARQQ $62.97
- TYRA N/A
- Revenue Growth
- ARQQ N/A
- TYRA N/A
- 52 Week Low
- ARQQ $3.72
- TYRA $6.42
- 52 Week High
- ARQQ $52.79
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- ARQQ 42.70
- TYRA 69.95
- Support Level
- ARQQ $27.29
- TYRA $9.96
- Resistance Level
- ARQQ $32.00
- TYRA $11.48
- Average True Range (ATR)
- ARQQ 2.04
- TYRA 0.72
- MACD
- ARQQ -0.18
- TYRA 0.22
- Stochastic Oscillator
- ARQQ 38.00
- TYRA 97.33
About ARQQ Arqit Quantum Inc.
Arqit Quantum Inc is a cybersecurity company that has pioneered a symmetric key agreement technology that makes the communications links of any networked device or data at rest secure against current and future forms of cyber attack - even an attack from a quantum computer. The company delivers its symmetric key agreement technology via its product SKA-Platform. The firm operates in one segment that is, the provision of cybersecurity services. The company operates and generates its revenue from UK.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.